Fig 1: Effect of Christchurch variant on ApoE‐induced tau pathology in the mouse retina. (A) Representative immunofluorescence of subretinally injected MAPT P301S tau transgenic mice with recombinant ApoE3 and ApoE3Ch variants, as compared to vehicle, showing reduced levels of AT8‐positive cells in the presence of the Ch variant. (B) Relative AT8+ tau levels in dissected retina isolated from mice treated with either vehicle, ApoE3, or ApoE3Ch, showing that in the presence of ApoE3Ch, AT8+ cells are significantly reduced (**p < 0.005, One‐way ANOVA, n = 3‐4). (C) immunofluorescence staining of intravitreal injected 9 months old MAPT P301S tau mice with recombinant ApoE3 and ApoE3 Ch proteins, showing the reduced levels of ptau S396‐positive cells in the presence of the Ch variant. (D) Intravitreal injection of ApoE3 Ch in the retina significantly decreased phosphorylation of tau (* = p < 0.05, one‐way ANOVA, n = 2–5). Vehicle treated wild‐type mice were used as control for MAPT P301S mice (PS19). For both panels A and C, nuclei are stained with DAPI in blue, vascular formation is stained with Isolectin (IB4) in green and tau phosphorylation are stained with AT8 anti tau (A) or ptau S396 antibody (C) in red. Scale bar = 50 µm. ANOVA, analysis of variance; ApoE3, apolipoprotein E3; ApoE3Ch, apolipoprotein E3 Christchurch variant; DAPI, 4′,6‐diamidino‐2‐phenylindole.
Fig 2: Ingenuity pathway analysis. (A) Comparative analysis of disease and biological function in ApoE3Ch versus ApoE3 WT interactors highlighting brain‐related disorders. (B) Comparison analysis of upstream regulators in ApoE3Ch versus ApoE3 WT interactors. (C) Pathway diagram with MAPT as the top upstream regulator showing indirect link to PSEN1, PSEN2, and APP, which are in turn linked to CTNNB1 and TP53. APP, amyloid precursor protein; ApoE3, apolipoprotein E3; ApoE3Ch, apolipoprotein E3 Christchurch variant; MAPT, microtubule‐associated protein tau; PSEN, presenilin; WT, wild‐type.
Fig 3: ApoE3 WT and ApoE3Ch differentially interacts with tau. (A, B) Number of MAPT fragments and sum intensity obtained via mass spectrometry analysis (*p ≤ 0.05, **p ≤ 0.01, Two‐way ANOVA, Fisher's LSD post‐hoc test, n = 3). (C) Co‐immunoprecipitation of human tau recombinant protein using His‐tag ApoE3 WT and ApoE3Ch proteins and detected via WB using anti‐tau antibody. (D) Representative Western blot of ApoE3 WT and ApoE3Ch after incubation with monomeric recombinant human tau or tau PFFs, arrows point the different tau aggregate bands. (E) Levels of FRET signal in tau RD P301S FRET Biosensor cells stimulated with tau PFF and treated with APOE3 variants (*p ≤ 0.05, **p ≤ 0.01, one‐way ANOVA, Fisher's LSD post‐hoc test, n = 6). (F) Scale bar: 100 µm. Representative maximum intensity projections of the live imaging acquisition of the tau aggregates in the tau RD P301S FRET Biosensor cells stimulated with tau PFFs and treated with the ApoE3 variants. (G) WB of tau aggregates in tau RD P301S FRET Biosensor cells treated with ApoE3 variants and ratio quantification between the total tau aggregates at ∼ 150 kDa of molecular weight and GAPDH, quantified bands are indicated by an arrowhead. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, one‐way ANOVA, Fisher's LSD post‐hoc test, n = 6). ANOVA, analysis of variance; ApoE3, apolipoprotein E3; ApoE3Ch, apolipoprotein E3 Christchurch variant; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase; LSD, least significant difference; PFF, preformed protofibrils; WB, Western blotting; WT, wild‐type.
Fig 4: PLNP-mTRIM11 treatment prevents early Tau pathology and preserves cognitive and behavioral function in young 3×Tg-AD mice(A) Experimental timeline: 5.5-month-old 3×Tg-AD mice received three intravenous injections of PLNP-mTRIM11 (2 mg mRNA equiv/kg) on days 0, 7, and 14. Behavioral and cognitive assessments were conducted starting on day 47.(B) Total distance traveled in the OFT (n = 8).(C and D) (C) Discrimination index and (D) PI in the NOR test (n = 8).(E and F) (E) Total platform crossings (n = 8) and (F) latency (n = 6) to platform in the MWM test.(G) Nesting behavior scores (n = 8), indicating motivation and executive function.(H) Quantitative expression of Tau, TRIM11, phosphorylated Tau (P-ser396), and Tau tangles (AT8) in hippocampal tissue following treatment (n = 3).(I) Representative immunohistochemical images of hippocampal sections stained for P-Ser396, AT8, GFAP (astrocytes), Iba-1 (microglia; scale bars, 100 μm), and NFL (axons; scale bars, 200 μm). Red arrows indicate positive immunostaining for AT8 (P-Ser202/Thr205), P-Ser396, Iba-1, GFAP, and NFL.(J) Quantification of Iba-1-positive microglia in the hippocampus. ELISA quantification of pro-inflammatory cytokines.(K–M) (K) TNF-α, (L) IL-1β, and (M) IL-6 in brain homogenates (n = 3).All data are expressed as mean ± SD.
Fig 5: PLNP-mTRIM11 treatment ameliorates Tau pathology, suppresses neuroinflammation, and protects neuronal integrity in 3×Tg-AD mice(A) Schematic overview of the experimental design for assessing insoluble Tau pathology in the hippocampus following treatment; mRNA dosage: 2 mg equiv/kg per injection.(B) IHC staining of phosphorylated Tau (P-ser396), Tau tangles (AT8), and TRIM11 in hippocampal sections collected 28 days after the final injection of PLNP-mTRIM11 or controls. Scale bars, 50 μm.(C–E) Quantification of TRIM11, P-ser396, and AT8 staining intensities in the hippocampus (n = 3).(F) Western blot analysis of Tau, TRIM11, phosphorylated Tau (P-ser396), and Tau tangle (AT8) expression in hippocampal lysates (n = 3).(G) Schematic illustration of TRIM11-mediated reduction in neuroinflammation via cytokine modulation.(H–J) ELISA quantification of (H) anti-inflammatory IL-10, (I) pro-inflammatory TNF-α, and (J) IL-6 levels in hippocampal tissue following treatment (n = 3).(K–M) (K) Representative IHC images and quantification of (L) astrocytic (GFAP) and (M) microglial (Iba-1) immunoreactivity in the hippocampus. Red arrows indicated activated microglia (Iba-1) and astrocytes (GFAP). Scale bars, 500 μm (n = 3).(N) Schematic representation of TRIM11’s neuroprotective function through suppression of NFL secretion.(O) Confocal imaging of NFL in hippocampal neurons reveals preserved axonal structure following PLNP-mTRIM11 treatment. Scale bars, 50 μm (n = 3).Data are presented as mean ± SD. mRNA dosage: 2 mg equiv./kg per injection.
Supplier Page from ACROBiosystems for Human Tau-441 / 2N4R Pre-formed Fibrils Protein, Tag Free